Abstract: The Bcl-2 family plays a crucial role in the endogenous pathway of apoptosis; the Bcl-2 protein is an apoptotic protein. Therefore, inhibitors targeting the Bcl-2 protein can promote cell apoptosis and be used to achieve antitumor goals. Venetoclax, the most widely used Bcl-2 inhibitor, has important effects, especially against chronic lymphocytic leukemia (CLL), and venetoclax administration can overcome some poor prognostic factors, such as unmutated IGHV and 17p deletions. In addition, it has therapeutic effects and a satisfactory safety profile for the treatment of mantle cell lymphoma (MCL), diffuse large B-cell lymphoma (DLBCL), and follicular lymphoma (FL).